Translations:Research/key-initiatives/ras/spokes-funding/9/en

From loveco.care
Revision as of 23:27, 29 October 2019 by FuzzyBot (talk | contribs) (Importing a new version from external source)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Channing Der and Adrienne Cox, University of North Carolina at Chapel Hill
Channing Der and Adrienne Cox, University of North Carolina at Chapel Hill, for "Identification of Synthetic Lethal Interactors in Pancreatic Cancer." Drs. Der and Cox and their team will use low-passage cell lines derived from patient-derived xenografts to discover synthetic lethalities in pancreatic cancer. In one aspect they will combine known inhibitors of KRAS effectors with a library of 500 clinical candidate and approved cancer drugs to find cytotoxic combinations that are specific for cells expressing mutant KRAS. Drug combinations will be tested in organoids and mouse models.